Page last updated: 2024-11-05

tilorone and Parapsoriasis

tilorone has been researched along with Parapsoriasis in 1 studies

Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.
tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.

Parapsoriasis: The term applied to a group of relatively uncommon inflammatory, maculopapular, scaly eruptions of unknown etiology and resistant to conventional treatment. Eruptions are both psoriatic and lichenoid in appearance, but the diseases are distinct from psoriasis, lichen planus, or other recognized dermatoses. Proposed nomenclature divides parapsoriasis into two distinct subgroups, PITYRIASIS LICHENOIDES and parapsoriasis en plaques (small- and large-plaque parapsoriasis).

Research Excerpts

ExcerptRelevanceReference
"Tilorone hydrochloride was used to treat eleven patients with T cell cutaneous disease ranging from pre-Sézary syndrome to tumor-stage mycosis fungoides."3.66Tilorone hydrochloride in the treatment of T cell lymphoproliferative cutaneous disease. ( Crotty, CP; Winkelmann, RK, 1982)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Crotty, CP1
Winkelmann, RK1

Other Studies

1 other study available for tilorone and Parapsoriasis

ArticleYear
Tilorone hydrochloride in the treatment of T cell lymphoproliferative cutaneous disease.
    Journal of the American Academy of Dermatology, 1982, Volume: 7, Issue:4

    Topics: Adult; Aged; Candida albicans; Female; Fluorenes; Humans; Lymphoproliferative Disorders; Male; Middl

1982